← All indications
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.
Drugs by status
Approved for this indication (1)
Phase 4 trials (17)
Phase 3 trials (14)
Phase 2 trials (44)
- azd9150
- ambrisentan
- fluorouracil
- paclitaxel
- lapatinib
- Filgrastim
- m0002
- oncorine
- sunitinib
- carboplatin
- endostatin
- sitagliptin
- sulfamethoxazole
- bevacizumab
- tumor necrosis factor
- urodilatin
- zoledronic acid
- bifidobacterium infantis
- bifidobacterium breve
- bifidobacterium longum
- lactobacillus plantarum
- vsl #3
- streptococcus salivarius
- methotrexate
- gimeracil
- oteracil
- eplerenone
- docetaxel
- cediranib
- oxaliplatin
- +14 more
Phase 1 trials (12)
Organizations
Organization Involved with Phase 4 Indications (36)
- Green Cross Corporation
- Grifols
- Norgine
- Otsuka
- Hanyang University
- Inje University
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Korea University
- Kyung Hee University
- Seoul National University
- Stanford University
- University of Florida
- University of Padova
- University of Southern Denmark
- University of Bologna
- Yonsei University
- Statens Serum Institut
- University of Copenhagen
- University of Vienna
- Chungnam National University
- Chung-Ang University
- Instituto Nacional de la Nutrición Salvador Zubiran
- Konkuk University
- Wonju Christian Hospital
- Catholic University of Korea
- University of Barcelona
- Soonchunhyang University
- Kyungpook University
- Hallym University
- Inha University
- +6 more
Organization Involved with Phase 3 Indications (29)
- Regeneron
- Sanofi
- Novartis
- BioVie Inc.
- Neovii Biotech
- National Cancer Institute (NCI)
- Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
- McGill University
- Nanjing University
- Postgraduate Institute of Medical Education and Research
- Tanta University
- University of Alberta
- Mayo Clinic
- Fudan University
- Jiao Tong University
- University of Toulouse
- University of Lille
- University of Lyon
- University of Reims
- University of Nice Sophia Antipolis
- Alfa Wassermann
- University of Paris
- Eurofins
- Jhaver Research Foundation Limited
- University of Rennes
- University of Antwerp
- People's Liberation Army of China
- University of Burgundy
- University of Franche-Comté
Organization Involved with Phase 2 Indications (34)
- Fresenius
- Genentech
- AIO-Studien-gGmbH
- Baxalta
- Galenic Research Institute Ltd
- Movetis
- Simcere Pharmaceutical Co., Ltd
- VSL Pharmaceuticals
- National Institutes of Health (NIH)
- National Cancer Institute, France
- National Heart, Lung, and Blood Institute (NHLBI)
- Region Skane
- Aarhus University
- Baylor University
- Clifford Hospital, Guangzhou, China
- Radboud University
- University of Nottingham
- University of Palermo
- Wuhan University
- University of Chicago
- Uppsala University
- University of Minnesota
- Karolinska Institute
- University of Turin
- Orebro University
- Pennsylvania State University
- University of Gothenburg
- Linkoping University
- San Giovanni Battista Hospital, Turin
- Bengbu Medical College
- +4 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (7)